In vitro and in vivo antitumor effects of recombinant bispecific antibodies based on humanized anti-EGFR antibody.
Watanabe, Yasuhiro; Asano, Ryutaro; Arai, Kyoko; Shimomura, Ippei; Ogata, Hiromi; Kawaguchi, Hiroko; Hayashi, Hiroki; Ohtsuka, Hideo; Yoshida, Hiroshi; Katayose, Yu; Egawa, Shinichi; Nakanishi, Takeshi; Umetsu, Mitsuo; Yasui, Hiroshi; Ishida, Tadao; Imai, Kohzoh; Kudo, Toshio; Unno, Michiaki; Kumagai, Izumi.
; 26(4): 949-55, 2011 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-21743971
Multifunctional Natural Killer Cell Engagers Targeting NKp46 Trigger Protective Tumor Immunity.
Tumor-directed immunotherapy can generate tumor-specific T cell responses through localized co-stimulation.
Opposites attract in bispecific antibody engineering.
Leverage nonclinical development of bispecifics by translational science.
A CD3-bispecific molecule targeting P-cadherin demonstrates T cell-mediated regression of established solid tumors in mice.
Harnessing T cells to fight cancer with BiTE® antibody constructs--past developments and future directions.
A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors.
LILRB1 Blockade Enhances Bispecific T Cell Engager Antibody-Induced Tumor Cell Killing by Effector CD8<sup>+</sup> T Cells.
Building blocks for bispecific and trispecific antibodies.
[Bispecific Antibodies: Formats and Areas of Application].